Clinical Trials Logo

Clinical Trial Summary

This is a research study looking at gene characteristics in blood and Pap smear samples in hopes of identifying markers that will predict if the HPV infection is present or not.


Clinical Trial Description

Because infection with high-risk human papillomavirus is a necessary cause of cervical cancer, HPV testing has many potential uses in cervical cancer screening. Unfortunately, like cytology, it suffers from a lack of specificity when used for population-based screening. Given that HPV testing detects more cases of CIN3+ than cytology and that it would probably be more practical in developing regions, finding a biomarker that would increase specificity has been the goal for much research on HPV and cervical cancer. The goal of this study is to explore potential predictors of viral clearance, specifically RNA levels of candidate genes in cervical swabs and host genetic polymorphisms, in the context of genotype-specific infection data. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00711815
Study type Observational
Source University of Alabama at Birmingham
Contact
Status Completed
Phase N/A
Start date January 2007
Completion date November 2010

See also
  Status Clinical Trial Phase
Completed NCT00956553 - Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Phase 4
Completed NCT05372016 - Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Phase 3
Recruiting NCT05027776 - Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years Phase 3
Suspended NCT00733122 - Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034) Phase 3
Recruiting NCT04895020 - Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years Phase 3
Recruiting NCT05371353 - Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Completed NCT03900572 - A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine Phase 1
Completed NCT00635830 - An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035) Phase 1
Not yet recruiting NCT01021904 - Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Phase 4
Completed NCT00378560 - V501 Efficacy Study in Women Aged 18 to 26 (V501-027) Phase 2
Completed NCT00682812 - Significance of the High-risk Hpv Viral Load N/A
Completed NCT01086709 - Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191
Completed NCT00834106 - Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) Phase 3
Completed NCT03085381 - A Phase I Study of Quadrivalent HPV Recombinant Vaccine Phase 1
Completed NCT00847340 - Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population N/A
Completed NCT00411749 - V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028) Phase 2
Completed NCT00943722 - A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Phase 3